Cardiff’s Move Into First-Line mCRC Backed By Data From Discontinued Study

Based on advice from the FDA, Cardiff is testing its PLK1 inhibitor onvansertib in first-line metastatic colorectal cancer; data from a discontinued second-line trial may support the hypothesis.

Metastatic cancer
Cardiff is working to develop the first new therapy for first-line mCRC in 20 years • Source: Shutterstock

Cardiff Oncology, Inc. expects to release top-line data from a Phase II study of its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) around mid-2024, but data from a discontinued study in second-line patients has provided evidence that the theory behind the ongoing trial is sound.

Key Takeaways
  • Cardiff is enrolling a Phase II study in first-line mCRC for its PLK1 inhibitor that it hopes will yield overall response data by mid-2024.

  • ...

The San Diego biotech has been waging a two-front battle as it tries to make its cash last long enough to prove that its PLK1 inhibitor can boost the effectiveness...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D